KRAS and lung carcinoma: Furthermore, mutant KRAS activates the NF-κB pathway, which leads to the upregulation of various cytokines and chemokines, such as IL-6, which plays a role in immune suppression in KRAS-driven lung cancer (Figure 7) [147].